Three cell lines all showed a significant increase in apoptosis when treated to prevent

which include the medial and orbital prefrontal cortices, amygdala, hippocampus, medial thalamus, and striatum, and cortico-cortical circuits from the medial prefrontal cortex connecting the parahippocampus, posterior cingulate and superior 850140-72-6 chemical information temporal cortices. In depression, volumetric and cellular deficits have most consistently been identified in the hippocampus, but as well in the anterior and posterior cingulate, orbitofrontal, lateral temporal and occipital cortices, and amygdala. However, the structural neuroanatomy only showed limited potential for diagnosis, suggesting that structural abnormalities in depression are slight in contrast to other psychiatric disorders, such as schizophrenia. Instead, functional brain activity to sad facial expressions may be a more accurate diagnostic marker of depression. A limitation of the present study was the small sample sizes in the prediction of clinical response, which may not have provided sufficient power to find an effect for CBT. Although such negative findings should be treated with caution, one interpretation would be that structural brain regions predictive of 848141-11-7 response to CBT, should they exist, may be more subtle than those predictive of fluoxetine response. Yet, as the sample for the CBT treatment group was sufficient to detect a predictive potential of functional MRI, it is possible that if structural effects exist, they might be more subtle than functional ones. Another limitation was that the pharmacological treatment was a single medication from the class of serotonergic reuptake inhibitors. The predictive potential for other antidepressant medications and from other classes requires further investigation. Moreover, the specificity of the predictive marker is somewhat equivocal as there was no placebo treatment arm. All patients in the present study were medication-free and suffering from an acute depressive episode at the time of the MRI scan. The generalisability of our findings to patients with more chronic forms of depression and the effects of medication from different classes, such as noradrenergic or combined noradrenergic and serotonergic mechanisms, require further investigation. In summary, the structural neural correlates of depression show high prognostic potential for treatment with the antidepressant medication fluoxetine. However, the diagnostic accuracy with structural neuroanatomy was more limited, while greater diagnostic potential may be found with functional neural correlate